HDAC11 and liver cancer: HDAC11 knockdown promotes histone acetylation in the related promoter region to increase the transcription of LKB1, consequently activating the signaling pathway of AMPK and hindering the glucose glycolytic pathway, which accordingly inhibits cancer stemness and liver cancer progression and increases sensitivity to sorafenib [29].